Clinical Trials Directory

Trials / Completed

CompletedNCT06932315

A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects

A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Adults

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
53 (actual)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This is a single-center, open-label and dose-escalation study to evaluate the safety, tolerability and dose-response relationship of HRS-9190 in healthy adults.

Conditions

Interventions

TypeNameDescription
DRUGHRS-9190 for InjectionSubject will receive the HRS-9190 injection at different dose levels.

Timeline

Start date
2025-04-23
Primary completion
2025-08-13
Completion
2025-08-13
First posted
2025-04-17
Last updated
2026-03-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06932315. Inclusion in this directory is not an endorsement.